Skip to main content
. 2021 Nov 22;11:742354. doi: 10.3389/fonc.2021.742354

Figure 4.

Figure 4

The expression of FUCA2 in PCa subgroups. (A) FUCA2 mRNA expression in different PCa subgroups. (B) The diagnostic value of FUCA2 for different PCa clinicopathological parameters. (C) Logical regression analysis of clinicopathological variables’ effects on low FUCA2 expression. IHC analysis of FUCA2 in low- (D) and high-grade (E) PCa tissue. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. **p < 0.01, ***p < 0.01. PCa, prostate cancer; IHC, immunohistochemistry.